Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $1,052.90

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-three analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation, fifteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $1,052.90.

REGN has been the topic of several research reports. Citigroup initiated coverage on Regeneron Pharmaceuticals in a report on Thursday, November 14th. They issued a “neutral” rating and a $895.00 price target on the stock. Oppenheimer reduced their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, Bank of America reissued an “underperform” rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th.

Regeneron Pharmaceuticals Stock Down 0.1 %

NASDAQ REGN opened at $714.47 on Thursday. Regeneron Pharmaceuticals has a 12 month low of $693.00 and a 12 month high of $1,211.20. The company has a market capitalization of $78.51 billion, a P/E ratio of 17.68, a PEG ratio of 2.19 and a beta of 0.08. The company’s 50 day simple moving average is $803.10 and its 200 day simple moving average is $988.80. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Institutional Trading of Regeneron Pharmaceuticals

Several large investors have recently modified their holdings of REGN. International Assets Investment Management LLC boosted its holdings in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares during the period. Worldquant Millennium Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $127,489,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of Regeneron Pharmaceuticals by 23.8% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock worth $525,804,000 after purchasing an additional 96,266 shares in the last quarter. TD Asset Management Inc increased its holdings in Regeneron Pharmaceuticals by 30.4% in the 2nd quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock valued at $369,484,000 after buying an additional 82,034 shares during the period. Finally, Icon Wealth Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 18,342.0% during the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after buying an additional 75,569 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.